<?xml version="1.0" encoding="UTF-8"?>
<ref id="B88">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Trimble</surname>
    <given-names>C. L.</given-names>
   </name>
   <name>
    <surname>Morrow</surname>
    <given-names>M. P.</given-names>
   </name>
   <name>
    <surname>Kraynyak</surname>
    <given-names>K. A.</given-names>
   </name>
   <name>
    <surname>Shen</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Dallas</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Yan</surname>
    <given-names>J.</given-names>
   </name>
   <etal/>
  </person-group>. (
  <year>2015</year>). 
  <article-title>Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial</article-title>. 
  <source>Lancet</source>
  <volume>386</volume>, 
  <fpage>2078</fpage>â€“
  <lpage>2088</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S0140-6736(15)00239-1</pub-id>
  <?supplied-pmid 26386540?>
  <pub-id pub-id-type="pmid">26386540</pub-id>
 </mixed-citation>
</ref>
